advertisement

Topcon

Abstract #117766 Published in IGR 24-4

Currently available prostanoids for the treatment of glaucoma and ocular hypertension: A review

Benitez B; Anter AM; Arcuri J; Bhattacharya SK
Current opinion in pharmacology 2024; 74: 102424


Recent advancements in prostaglandin analogs (PGAs) have reinforced their role in managing intraocular pressure (IOP). Latanoprost excels in 24-h IOP control, while various PGAs offer similar effectiveness and side effects, generic PGAs perform as well as branded ones, and a notable IOP rise observed upon PGA discontinuation. Formulations with or without preservatives show comparable IOP reduction and adherence, often surpassing benzalkonium chloride (BAK)-preserved options. Emergent PGAs, such as latanoprostene bunod, fixed-dose netarsudil combined with latanoprost, and omidenepag Isopropyl, offer enhanced or non-inferior IOP reduction. The bimatoprost implant introduces a novel administration method with effective IOP reduction. These developments underscore ongoing progress in PGA-focused ophthalmological research. This article offers a comprehensive review of available prostanoid analogs and explores new developments.

Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, 33136, USA; Miami Integrative Metabolomics Research Center, Miami, FL, 33136, USA.

Full article

Classification:

15 Miscellaneous



Issue 24-4

Change Issue


advertisement

Nidek